I

IX Biopharma Ltd
SGX:42C

Watchlist Manager
IX Biopharma Ltd
SGX:42C
Watchlist
Price: 0.122 SGD Market Closed
Market Cap: 116.6m SGD

IX Biopharma Ltd
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

IX Biopharma Ltd
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
I
IX Biopharma Ltd
SGX:42C
Non-Reccuring Items
S$7k
CAGR 3-Years
-42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WAVE Life Sciences Ltd
NASDAQ:WVE
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Haw Par Corporation Ltd
SGX:H02
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hyphens Pharma International Ltd
SGX:1J5
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

IX Biopharma Ltd
Glance View

Market Cap
108.3m SGD
Industry
Pharmaceuticals

iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.

42C Intrinsic Value
0.033 SGD
Overvaluation 73%
Intrinsic Value
Price
I

See Also

What is IX Biopharma Ltd's Non-Reccuring Items?
Non-Reccuring Items
7k SGD

Based on the financial report for Jun 30, 2025, IX Biopharma Ltd's Non-Reccuring Items amounts to 7k SGD.

What is IX Biopharma Ltd's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
-42%

The average annual Non-Reccuring Items growth rates for IX Biopharma Ltd have been -42% over the past three years .

Back to Top